Colorectal Cancer Payment Fairness Act
Congress Moves to Make Certain Medicare Colorectal Cancer Screening Tests Free to Patients
Stalled
No legislative action in over 90 days.
Legislative Progress
Key Points
- Congress would remove the coinsurance (the patient share) for certain colorectal cancer screening tests under Medicare.
- The bill makes Medicare pay 100% for these specific screening tests each year, instead of less than the full cost.
- For many older adults, this could mean no out-of-pocket cost for covered colorectal cancer screening tests, making it easier to get screened.
- It updates current law by extending the full-coverage approach past the current time limits set in the Medicare rules.
Impact Analysis
Personal Impact
How this policy affects specific groups of people
Milestones
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
Related News
2 articles
Congresswoman Watson Coleman Introduces Colorectal Cancer Payment Fairness Act
Press release announcing introduction of the Colorectal Cancer Payment Fairness Act to eliminate Medicare coinsurance for certain colorectal cancer screening tests.

Booker, Watson Coleman, Fitzpatrick, Carter Introduce Bipartisan Colorectal Cancer Payment Fairness Act
Announcement of legislation aiming to eliminate coinsurance payments under Medicare for colorectal cancer screening tests.
Source Information
Document Type
Congressional Bill
Official Title
Colorectal Cancer Payment Fairness Act
Data Sources
Sponsor
Cosponsors
(2)Analysis generated by AI. Always verify with official sources.